2022 World Conference on Lung Cancer (ePosters)-EP16.02-012. cfDNA Analysis Implementation in Early Stage Lung Cancer

Pdf Summary

This study aimed to investigate the impact of cell-free tumor DNA (cfDNA) analysis in early-stage lung cancer. A cohort of 40 patients with early-stage lung cancer was recruited, and blood samples were collected at different time points throughout the treatment process. The researchers assessed the expression of cfDNA and the presence of actionable mutations.<br /><br />The results showed that the highest sensitivity in liquid biopsies was observed at the pre-operatory timepoint. The average yield of cfDNA obtained varied across the different time points, with the highest yield observed at the surgical discharge. However, the liquid biopsies taken at surgical discharge did not detect the actionable mutations identified in the tissue biopsies. This suggested that the cfDNA detected at this time point originated from the traumatic and inflammatory events associated with the surgical procedure, rather than from the tumor itself.<br /><br />Based on these findings, the study highlights the importance of the pre-operatory timepoint for the sensitivity of liquid biopsies in monitoring early-stage lung cancer. It suggests that liquid biopsies taken at surgical discharge may not be suitable for detecting actionable mutations.<br /><br />Overall, the study provides insights into the implementation of cfDNA analysis in early-stage lung cancer and emphasizes the need to consider the timing and origin of cfDNA samples. Further research is necessary to fully understand the potential of liquid biopsies in monitoring surgically resectable lung cancer.

Asset Subtitle

Joana Espiga de Macedo

Meta Tag

Speaker Joana Espiga de Macedo

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

cell-free tumor DNA

cfDNA analysis

early-stage lung cancer

liquid biopsies

blood samples

actionable mutations

pre-operatory timepoint

surgical discharge

traumatic and inflammatory events

monitoring surgically resectable lung cancer